Literature DB >> 2606916

Expression and characterization of pro alpha 2-plasmin inhibitor.

Y Sumi1, Y Ichikawa, Y Nakamura, O Miura, N Aoki.   

Abstract

alpha s-Plasmin inhibitor (alpha 2PI), one of the serine protease inhibitors in plasma, was expressed in baby hamster kidney (BHK) cell line. The expression vector was constructed with its genomic DNA and cDNA, and was transfected into BHK cells by the calcium phosphate method. The recombinant alpha 2PI which was secreted from the cells was estimated by SDS-PAGE to have a molecular mass of 67 kDa, which is indistinguishable from that of normal plasma alpha 2PI. The leader peptide of 12 amino acids was retained at the amino terminus of the recombinant alpha 2PI. This finding suggests that alpha 2PI has pre-pro type processing and the propeptide of 12 amino acids is not removed in BHK cells. This pro-alpha 2PI shows essentially the same inhibitory activity on plasmin and the same affinity for plasmin(ogen) as those of normal alpha 2PI. However, the cross-linking ability to fibrin is reduced to less than one-third of that of normal alpha 2PI. The cross-linking site is the glutamine residue located at the second position from the amino terminus of normal alpha 2PI. The conformational change of this region caused by the addition of the propeptide may have affected the cross-linking capacity of the inhibitor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606916     DOI: 10.1093/oxfordjournals.jbchem.a122920

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  13 in total

1.  Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.

Authors:  K Bangert; A H Johnsen; U Christensen; S Thorsen
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

2.  The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.

Authors:  Simon S Gerber; Sofia Lejon; Michael Locher; Johann Schaller
Journal:  Cell Mol Life Sci       Date:  2010-01-29       Impact factor: 9.261

Review 3.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

4.  An examination of the inhibitory mechanism of serpins by analysing the interaction of trypsin and chymotrypsin with alpha 2-antiplasmin.

Authors:  J J Enghild; Z Valnickova; I B Thøgersen; S V Pizzo; G Salvesen
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

5.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

6.  The kidney is a major site of alpha(2)-antiplasmin production.

Authors:  P A Menoud; N Sappino; M Boudal-Khoshbeen; J D Vassalli; A P Sappino
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  Evaluation of Fibrinolytic Inhibitors: Alpha-2-Antiplasmin and Plasminogen Activator Inhibitor 1 in Patients with Obstructive Sleep Apnoea.

Authors:  Maciej Zakrzewski; Ewelina Zakrzewska; Paweł Kiciński; Sylwia Przybylska-Kuć; Andrzej Dybała; Wojciech Myśliński; Jolanta Pastryk; Tomasz Tomaszewski; Jerzy Mosiewicz
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

Review 8.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

9.  Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.

Authors:  Piet Meijer; Michel Hanss; Ulla Christensen; Bjorn Wiman; Kees Kluft
Journal:  EJIFCC       Date:  2001-07-22

Review 10.  Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.

Authors:  Fahad S M Alshehri; Claire S Whyte; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.